内皮素受体拮抗药对蛛网膜下腔出血患者的脑血管保护作用  

Protection Effect of Endothelin Receptor Antagonist on Blood Vessel in Patients with Subarachnoid Hemorrhage

作　　者：王正军[1] 刘光健[2] 

机构地区：[1]湖北医药学院附属太和医院药学部,十堰市442000 [2]湖北医药学院附属太和医院神经内科,十堰市442000

出　　处：《中国药房》2011年第6期525-529,共5页China Pharmacy

摘　　要：目的:评价内皮素受体拮抗药(ETRA)预防和治疗脑血管痉挛的效果。方法:对随机双盲安慰剂对照临床试验进行系统评价和荟萃分析。结果:3个研究符合纳入标准,861例完成了试验观察。ETRA组脑血管痉挛、迟发性缺血性神经功能缺损和迟发性神经功能缺损,以及新发脑梗死的风险分别为安慰剂组的58%(RR=0.58,95%CI:0.48～0.71,P<0.00001),76%(RR=0.76,95%CI:0.60～0.96,P=0.02)和47%(RR=0.47,95%CI:0.28～0.78,P=0.003);2组患者临床转归没有差异(死亡:RR=1.08,95%CI:0.72～1.63,P=0.71;死亡、植物状态和严重残疾:RR=0.91,95%CI:0.72～1.13,P=0.39)。结论:ETRA极大降低了蛛网膜下腔出血患者脑血管痉挛的风险,但是,目前尚无证据表明ETRA可以改善患者的临床转归。OBJECTIVE: To investigate the preventive and therapeutic efficacy of endothelin receptor antagonist (ETRA) on cerebral vasospasm. METHODS: The therapeutic efficacy of ETRA in the treatment of cerebral vasospasm was evaluated through system evaluation and Meta-analysis of clinical randomized double-blind controlled trials. RESULTS: 3 studies were enrolled and observation test was completed in 861 patients. The risk of cerebral vasospasm,delayed ischemic neurological deficit(DIND)& delayed neurological defici...

关 键 词：蛛网膜下腔出血 脑血管痉挛 内皮素受体拮抗药 临床转归 不良反应 荟萃分析 

分 类 号：R96[医药卫生—药理学]